{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:17:58Z","timestamp":1787894278504,"version":"build-2784847793"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiovascular disease is the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D). While statin therapy is universally recommended for cardiovascular disease prevention, its potential adverse effects on glycemic progression remain controversial, particularly in patients with newly diagnosed disease. This study aimed to evaluate the dual effects of statin initiation on glycemic control and major adverse cardiovascular events (MACEs) in a retrospective cohort of patients with new-onset T2D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study in which patients who were newly diagnosed with T2D between January 2018 and December 2020 were screened. The primary outcome was the change in the glycated hemoglobin (HbA1c) levels. Secondary outcomes included fasting plasma glucose (FPG) levels, 2-hour post-prandial glucose (2hPG) levels, diabetes therapy intensification, insulin initiation, hyperglycemic crisis, and MACEs. Longitudinal glycemic trajectories were assessed using two-way repeated-measures ANOVA. The MACE risk was evaluated with a Kaplan\u2013Meier analysis and multivariable Cox regression model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 604 eligible patients were classified into a statin group (n = 458) and a nonstatin group (n = 146). At the 6-month follow-up, both groups exhibited improved glycemic indices, but this improvement was significantly attenuated in the statin group. Similar attenuated improvements were observed in the FPG and 2hPG levels at 6 months. Group \u00d7 time interaction effects were significant for FPG, 2hPG, and HbA1c levels at 6 months. By 60 months, between-group differences in HbA1c levels were no longer significant. During the median (interquartile range) follow-up of 73 (68\u201380) months, statin therapy was associated with higher frequencies of diabetes therapy intensification (33.3% vs. 22.6%, p = 0.016), insulin initiation (21.5% vs. 12.3%, p = 0.015), and hyperglycemic crisis (8.5% vs. 3.4%, p = 0.039). Despite these metabolic disadvantages, statin therapy was independently associated with a lower MACE risk according to the multivariable Cox regression analysis (HR 0.41, 95% CI 0.21\u20130.83; p = 0.013).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with new-onset T2D, early statin initiation is associated with worse short-term glycemic improvement and a greater need for escalating glucose-lowering therapy; however, it is also associated with a substantial reduction in the long-term MACE risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1921249","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:33:07Z","timestamp":1787891587000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of statins on glycemic control and cardiovascular events in patients with new-onset type 2 diabetes: a retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Ying","family":"Ran","sequence":"first","affiliation":[{"name":"Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ran","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lupin","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Ran","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hejun","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaofa","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Ling","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(75)90692-x","article-title":"Diabetes and cardiovascular disease. The Framingham study","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S010","article-title":"Cardiovascular disease and risk management: Standards of care in diabetes-2024","volume":"47","author":"ElSayed","year":"2024","journal-title":"Diabetes Care"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.4.614","article-title":"Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)","volume":"20","author":"Py\u00f6r\u00e4l\u00e4","year":"1997","journal-title":"Diabetes Care"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.98.23.2513","article-title":"Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators","volume":"98","author":"Goldberg","year":"1998","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3528-5","article-title":"Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: A 6 year follow-up study of the METSIM cohort","volume":"58","author":"Cederberg","year":"2015","journal-title":"Diabetologia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2012.06.001","article-title":"Statins are diabetogenic--myth or reality","volume":"13","author":"Sattar","year":"2012","journal-title":"Atheroscler Suppl"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2009.10.008","article-title":"Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis","volume":"87","author":"Baker","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702397","article-title":"Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells","volume":"126","author":"Yada","year":"1999","journal-title":"Br J Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011320","article-title":"Time- and dose-dependent association of statin use with risk of clinically relevant new-onset diabetes mellitus in primary prevention: A nationwide observational cohort study","volume":"8","author":"Ko","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"B15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12933-023-01921-5","article-title":"Triglycerides and risk of cardiovascular events in statin-treated patients with newly diagnosed type 2 diabetes: A Danish cohort study","volume":"22","author":"Kristensen","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S002","article-title":"Diagnosis and classification of diabetes: Standards of care in diabetes-2024","volume":"47","author":"ElSayed","year":"2024","journal-title":"Diabetes Care"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam Clin Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12916-022-02316-1","article-title":"Assessment of glycemia in chronic kidney disease","volume":"20","author":"Hassanein","year":"2022","journal-title":"BMC Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.5714","article-title":"Association of statin therapy initiation with diabetes progression: A retrospective matched-cohort study","volume":"181","author":"Mansi","year":"2021","journal-title":"JAMA Intern Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S275552","article-title":"Hyperglycemic crisis characteristics and outcome of care in adult patients without and with a history of diabetes in Tigrai, Ethiopia: Comparative study","volume":"14","author":"Gebremedhin","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0032","article-title":"Hyperglycemic crises in adults with diabetes: A consensus report","volume":"47","author":"Umpierrez","year":"2024","journal-title":"Diabetes Care"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3374-x","article-title":"Statins and glycaemic control in individuals with diabetes: A systematic review and meta-analysis","volume":"57","author":"Erqou","year":"2014","journal-title":"Diabetologia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00040-8","article-title":"Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: An individual participant data meta-analysis","volume":"12","author":"Reith","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.10.047","article-title":"Predictors of new-onset diabetes in patients treated with atorvastatin: Results from 3 large randomized clinical trials","volume":"57","author":"Waters","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.103.3.357","article-title":"Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study","volume":"103","author":"Freeman","year":"2001","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S009","article-title":"Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2024","volume":"47","author":"ElSayed","year":"2024","journal-title":"Diabetes Care"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1089\/met.2012.0177","article-title":"Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3T3-L1 adipocytes","volume":"11","author":"Ganesan","year":"2013","journal-title":"Metab Syndr Relat Disord"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0269-5","article-title":"Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): Implications in glycaemic control","volume":"49","author":"Nakata","year":"2006","journal-title":"Diabetologia"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-25-0048","article-title":"From cholesterol to glucose: Uncovering how statins induce \u03b2-cell dysfunction to promote type 2 diabetes","volume":"266","author":"Barrow","year":"2025","journal-title":"J Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2014.02.014","article-title":"Statin treatment and new-onset diabetes: A review of proposed mechanisms","volume":"63","author":"Brault","year":"2014","journal-title":"Metabolism"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000348","article-title":"Statins and higher diabetes mellitus risk: Incidence, proposed mechanisms, and clinical implications","volume":"29","author":"Guber","year":"2021","journal-title":"Cardiol Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.79a.12091","article-title":"Statins and diabetes risk: Fact, fiction, and clinical implications","volume":"79","author":"Rocco","year":"2012","journal-title":"Cleve Clin J Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1921249\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:33:12Z","timestamp":1787891592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1921249\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":36,"alternative-id":["10.3389\/fendo.2026.1921249"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1921249","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"1921249"}}